Home / Stocks / PTGX

Protagonist Therapeutics (PTGX, Biotechnology) Stock Valuation & Fair Value Significantly overvalued

Protagonist Therapeutics (PTGX, Biotechnology) trades at a blended P/E of 49.0, about 436% above its historical normal valuation, with a forward growth estimate of -20.7%. Analysts' one-year estimates have been hit 22% of the time. Priced at its historical normal P/E of 9.1 on the same blended earnings, the 2026-09-18 close of $143.00 corresponds to about $26.70 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
49.0
Normal P/E
9.1
PEG
—
Fwd growth
-20.7%
Div yield
0.0%
RSI (14)
39.5
Neutral
Technical context
  • Price $138.70 at the 2026-09-23 close, 5.0% below the 20-day average ($145.98) and 3.7% below the 50-day ($144.09).
  • RSI (14) at 39.5.
  • 52-week range $64.00 to $158.62: the price is 12.6% below the high and 116.7% above the low.

The Street vs SeerForecast

Wall Street's mean price target for PTGX is $174.69 across 13 analysts, 25.9% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-09-14.

Blended P/E and rating by weekBlended P/E moved from 53.2 to 49.0 between 2026-09-14 and 2026-09-21, against a normal P/E of 9.1, with 0 rating changes over 3 recorded weeks.2026-09-14: P/E 53.2, Significantly overvalued2026-09-19: P/E 53.2, Significantly overvalued (recalculated)2026-09-21: P/E 49.0, Significantly overvalued20.040.0Sep 14Sep 16Sep 18Sep 19Sep 21Normal P/E 9.1
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-14P/E 53.2+482%Significantly overvalued
2026-09-19P/E 53.2+482%Significantly overvalued
2026-09-21P/E 49.0+436%Significantly overvalued ← now

Frequently asked questions

Is Protagonist Therapeutics stock overvalued?

At a blended P/E of 49.0 versus its historical normal P/E of 9.1, Protagonist Therapeutics trades about 436% above its typical valuation. tickerseer currently rates it significantly overvalued.

What is Protagonist Therapeutics's fair value and PEG?

Protagonist Therapeutics trades at a blended P/E of 49.0 against a historical normal P/E of 9.1, a forward growth estimate of -20.7%. Priced at its historical normal P/E of 9.1 on the same blended earnings, the 2026-09-18 close of $143.00 corresponds to about $26.70 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Protagonist Therapeutics changed?

tickerseer's rating has been significantly overvalued since 2026-09-14.

What is the analyst price target for Protagonist Therapeutics?

The mean Wall Street price target for Protagonist Therapeutics is $174.69 across 13 analysts, 25.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track PTGX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.